737 N. Michigan Ave., Suite 800
Chicago, IL 60611
© 2022 All Rights Reserved.
Program Track: Tissue Engineering and Hard Tissue Reconstruction
Gustavo Avila Ortiz
The AAP recently completed a Best Evidence Consensus (BEC) meeting on the use of biologics in contemporary periodontal practice. The goal of this BEC was to provide an updated perspective on the therapeutic use of autologous-blood derived products (ABPs), enamel matrix derivatives (EMD), platelet-derived growth factor-BB (PDGF-BB), and bone morphogenetic protein 2 (BMP-2) for the treatment of mucogingival deformities and periodontal infrabony defects, and for alveolar ridge preservation and implant site development. This session is aimed at providing an overview of the main findings of three comprehensive literature reviews and the actual expert consensus. This information can help with clinical decision making and treatment planning involving the use of biologics in daily practice.
• Identify the clinical indications of different biologics currently available for use in clinical practice.
• Know the evidence supporting the use of biologics for the treatment of mucogingival deformities and periodontal infrabony defects, and for alveolar ridge preservation and implant site development.
• Recognize the benefits, limitations, and potential risks associated with the use of biologics in periodontal practice.
Thank you to BioHorizons, Geistlich, Lynch Biologics, and Straumann for supporting the AAP’s Best Evidence Consensus on Biologics